Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Conflicting data on digoxin's effect on mortality in heart failure (HF) and atrial fibrillation (AF) exists.
• Older randomized controlled trials (RCTs) showed decreased hospitalizations but no effect on all-cause mortality.
• Recent meta-analyses have linked digoxin to increased mortality, narrowing its clinical application.

Purpose of the Study:

• To provide a literature perspective on digoxin use in HF and AF.
• To address the polarization among providers regarding digoxin's efficacy.
• To evaluate the quality of studies on digoxin's impact on patient outcomes.

Main Methods:

• Literature review and analysis.
• Focus on the quality of both older RCTs and recent meta-analyses.
• Synthesis of evidence regarding digoxin's effects on various patient outcomes.

Main Results:

• High-quality RCT data suggest digoxin improves functional capacity and symptom management in HF/AF patients.
• Digoxin use is associated with reduced hospitalizations and fewer HF-related deaths.
• Potential overall mortality benefit observed within therapeutic serum digoxin concentrations, particularly in high-risk patients (EF < 25%, NYHA Class II-IV).

Conclusions:

• RCTs, with minimized confounding factors, indicate positive outcomes with digoxin.
• Further well-designed RCTs are needed to clarify digoxin's impact on mortality, hospitalizations, and symptom management.
• Evidence supports careful consideration of digoxin in specific HF and AF patient populations.